BioCryst Pharmaceuticals (BCRX) Jefferies London Healthcare Conference 2024 summary

Business performance and financial outlook

• Achieved strong global net revenue guidance of $430–$435 million for the year, with a path to $1 billion in peak global revenue and a 20% CAGR through the decade.

• Raised annual revenue guidance due to robust demand and improved paid therapy rates, especially in the U.S.

• Targeting profitability this year, with expectations to be EPS positive in the second half of next year and fully cash flow positive by 2026.

• Ended the period with $353 million in cash, supporting ongoing investments and independence from capital markets.

Commercial strategy and market dynamics

• Orladeyo is the only oral prophylactic for HAE, maintaining strong demand and consistent growth in patient numbers.

• Paid therapy rates improved to 74.8% overall and 82% among commercially insured patients; aiming for 85% within three years, with Medicare changes as a potential tailwind.

• Retention rates for Orladeyo are 60–70% at 12 months, comparable or superior to competitors, supported by patient education and expectation management.

• Over 50% of new patients switch from other prophylactics, with steady uptake across acute-only and therapy-naive segments.

• Market research predicts Orladeyo and Takhzyro will remain market leaders through 2033, with new entrants unlikely to displace them due to convenience and efficacy.

Pipeline development and R&D updates

• Advancing BCX17725 for Netherton syndrome, targeting KLK5 at the top of the disease pathway; phase 1 healthy volunteer study underway, with patient data expected in 2025.

• KLK5 inhibition seen as a superior approach versus downstream targets, with BCX17725 showing high potency and potential competitive advantages.

• Anticipates reporting safety, PK, and skin penetration data in 2025, followed by clinical outcomes in patients.

• Avoralstat for diabetic macular edema (DME) to enter human trials next year, using suprachoroidal injection for targeted delivery and long-acting effect.

• Key milestones ahead include DME patient data by year-end, BCX17725 data late next year, and continued quarterly updates on Orladeyo’s growth.